If the data from recent ongoing clinical studies of the immunotherapies are accumulated, better therapeutic targeting associated with PD-1/PD-L1 pathways will be available for patients with DLBCL. The gene discussed is PDCD1; the disease is diffuse large B-cell lymphoma.